Zinc Sulfate

Sickle Cell Disease

Indiana UniversitySmall moleculePhase 2/3Active

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 65/ 100

Competitive context

132 Active assets in the Sickle Cell Disease cohort.

Asset / Sponsor	Phase	Rating
Glutamine Ain Shams University	Phase 4	BBB
Hydroxyurea St. Jude Children's Research Hospital	Phase 4	BB
Crizanlizumab Novartis Pharmaceuticals	Phase 4	BB
Magnesium Metallicum Medical College of Wisconsin	Phase 3	BB
Nivestim St. Jude Children's Research Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Zinc Sulfate is also rated in:

acquired immunodeficiencyDormant

BB

Indicative · Phase 4

69 / 100

thalassemiaDormant

BB

Indicative · Phase 4

68 / 100

disease related to hematopoietic stem cell transplantDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.